Mississauga, ON -- (SBWire) -- 12/04/2013 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Lightlake Therapeutics Clinical Trial Supports Nasal Spray Version of Naloxone for Opioid Overdose Treatment.”
Companies mentioned in this article include Lightlake Therapeutics Inc. (OTCBB:LLTP).
Article Excerpt:
The Centers for Disease Control and Prevention has determined that prescription drug abuse in the U.S. has reached epidemic proportion, citing an increase in opioid analgesic sales as a contributing factor. In 2010, drug poisoning, mostly in the form of overdoses, was attributed to more deaths than motor vehicle accidents in 31 states, according to CDC data. Deaths from prescribed opioid analgesics for the country totaled an amazing 16,651 in 2010, and that’s just specified deaths. It’s presumable that the drugs played a role in the 25-percent of drug-related deaths where an exact cause wasn’t provided. For comparison, in 1999, there were only 4,030 deaths from prescription opioid overdose.
The CDC and Drug Enforcement Agency are working together to combat the growing rate of opioid abuse that is rising in tandem with overdose deaths. Tackling increasing overdose rates from a different angle, drug developers, such as Lightlake Therapeutics Inc. (OTCBB:LLTP), are working on innovative ways to rapidly reverse the overdose of prescription and illicit opioids.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/412/lightlake-therapeutics-clinical-trial-supports-nasal-spray-version-of-naloxone-for-opioid-overdose-treatment.htm
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
All Penny Stocks.com News: Lightlake Therapeutics Clinical Trial Supports Nasal Spray Version of Naloxone for Opioid Overdose Treatment